Home Cart Sign in  
Chemical Structure| 83-48-7 Chemical Structure| 83-48-7

Structure of Stigmasterol
CAS No.: 83-48-7

Chemical Structure| 83-48-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Stigmasterol is among the most abundant of plant sterols used as a food additive, with potential effect on lowering the levels of LDL cholesterol.

Synonyms: Stigmasterin; 5,22-Cholestadien-24-beta-ethyl-3-beta-ol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Stigmasterol

CAS No. :83-48-7
Formula : C29H48O
M.W : 412.69
SMILES Code : CC[C@](C(C)C)([H])/C([H])=C([H])/[C@@]([C@@]1([H])CC[C@@]2([H])[C@]([C@]3([H])CC[C@]12C)([H])CC=C4C[C@](O)([H])CC[C@@]43C)([H])C
Synonyms :
Stigmasterin; 5,22-Cholestadien-24-beta-ethyl-3-beta-ol
MDL No. :MFCD00003630
InChI Key :HCXVJBMSMIARIN-PHZDYDNGSA-N
Pubchem ID :5280794

Safety of Stigmasterol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
B16F10 cells 0.5-50 µg/mL 1 hour To evaluate the inhibitory effect of STIG on H2O2-induced ROS levels. Results showed STIG significantly reduced H2O2-induced ROS levels. Antioxidants (Basel). 2024 Mar 21;13(3):380
LS174T human colon cancer cells 200 mM 16 hours Evaluate the activity of stigmasterol as an LXR agonist in human intestinal cells, results showed stigmasterol could induce the expression of LXR target gene ABCA1. J Nutr Biochem. 2020 Feb;76:108263
L6 cells 40 μg/mL 20 minutes Evaluate the effect of stigmasterol on GLUT4 translocation, results showed that stigmasterol treatment increased fluorescence intensity on L6 cell membranes, indicating enhanced GLUT4 translocation activity. Food Nutr Res. 2017 Aug 23;61(1):1364117
U87 GBM cells 10, 20, 40, 80, 120, 160, 200, 240 µM 24 and 48 hours Stigmasterol suppressed the proliferation of GBM cells in a dose- and time-dependent manner. Mol Med Rep. 2024 Dec;30(6):227
B16F10 cells 20 µg/mL 24 hours To evaluate the effect of STIG on PD-L1 expression. Results showed STIG significantly reduced IFN-γ-induced PD-L1 mRNA and protein levels. Antioxidants (Basel). 2024 Mar 21;13(3):380
L6 cells 10, 20, 40 μg/mL 24 hours Detect the effect of stigmasterol on glucose uptake, results showed that stigmasterol increased glucose uptake in a concentration-dependent manner. Food Nutr Res. 2017 Aug 23;61(1):1364117
RAW264.7 cells 15 µM 24 hours To investigate the effect of stigmasterol-treated LPS-induced Schwann cell-conditioned medium on the proliferation and migration of RAW264.7 cells. Results showed that L-S-CM significantly inhibited the proliferation and migration of RAW264.7 cells. CNS Neurosci Ther. 2024 Apr;30(4):e14657
RSC96 cells 15 µM 24 hours To investigate the effect of stigmasterol on IL-34 secretion in LPS-induced RSC96 cells. Results showed that stigmasterol significantly reduced the secretion of IL-34 in LPS-induced RSC96 cells. CNS Neurosci Ther. 2024 Apr;30(4):e14657
OV90 cells 0, 5, 10, 20 μg/mL 24 hours Induced apoptosis, activated caspase-3 and caspase-9 Pharmaceutics. 2020 May 28;12(6):488
ES2 cells 0, 5, 10, 20 μg/mL 24 hours Induced apoptosis, activated caspase-3 and caspase-9 Pharmaceutics. 2020 May 28;12(6):488
Ishikawa cells 10 μg/ml 24 hours Stigmasterol enhances the sensitivity of endometrial cancer cells to cisplatin by suppressing Nrf2 expression Antioxidants (Basel). 2022 Jan 20;11(2):199
Ishikawa cells 10 μg/ml 24 hours Stigmasterol enhances the sensitivity of endometrial cancer cells to cisplatin by suppressing Nrf2 expression Cancer Cell Int. 2020 Oct 6;20:480
U87 GBM cells 240 µM 24 hours Stigmasterol significantly reduced free fatty acid and total cholesterol levels in U87 GBM cells. Mol Med Rep. 2024 Dec;30(6):227
U87 GBM cells 240 µM 24 hours Stigmasterol significantly inhibited vasculogenic mimicry formation in U87 GBM cells. Mol Med Rep. 2024 Dec;30(6):227
U87 GBM cells 240 µM 24 hours Stigmasterol significantly inhibited the migration ability of U87 GBM cells. Mol Med Rep. 2024 Dec;30(6):227
U87 GBM cells 240 µM 24 hours Stigmasterol significantly reduced the number of invasive U87 GBM cells. Mol Med Rep. 2024 Dec;30(6):227
U87 GBM cells 240 µM 24 hours Stigmasterol significantly increased the proportion of apoptotic U87 GBM cells. Mol Med Rep. 2024 Dec;30(6):227
4T1 isolated breast cancer stem-like cells 0, 1, 5, 10 µM 24 hours Inhibits spheroid formation ability, cell viability, and migration ability, promotes cell apoptosis J Cancer. 2025 Feb 3;16(5):1618-1630
SUM159 isolated breast cancer stem-like cells 0, 1, 5, 10 µM 24 hours Inhibits spheroid formation ability, cell viability, and migration ability, promotes cell apoptosis J Cancer. 2025 Feb 3;16(5):1618-1630
Mouse chondrogenic cells (ATDC5 cells) 5, 10, 20, 40 μg/mL 24 hours To detect the effect of stigmasterol on the viability of ATDC5 cells, the results showed that 0-20 μg/ml STM had no significant effect on cell viability, while 40 μg/ml STM showed inhibitory effects. Bioengineered. 2021 Dec;12(2):9332-9340
Liver epithelial cells THLE-2 10, 50, 100 µg/mL 48 hours Assessed cytotoxicity and metabolic activity, showing DP3SSt inhibited cell proliferation and viability at 50 and 100 µg/mL, while other derivatives had no significant effect Sci Rep. 2023 Dec 4;13(1):21375
Colon mucosa cells CCD 841CoN 10, 50, 100 µg/mL 48 hours Assessed cytotoxicity and metabolic activity, showing no toxicity from unheated and heated Stigmasterol derivatives, with DO3SSt promoting cell proliferation at specific concentrations Sci Rep. 2023 Dec 4;13(1):21375
Small intestine epithelial cells FHS 74Int 10, 50, 100 µg/mL 48 hours Assessed cytotoxicity and metabolic activity, showing no toxicity from unheated and heated Stigmasterol derivatives, with DO3SSt promoting cell proliferation at specific concentrations Sci Rep. 2023 Dec 4;13(1):21375
MGC-803 10, 20 µM 48 hours To evaluate the effect of Stigmasterol on cell proliferation, results showed that Stigmasterol significantly inhibited cell viability in a time- and dose-dependent manner in MGC-803 cells. Front Oncol. 2021 Feb 23;11:629008
SGC-7901 10, 20 µM 48 hours To evaluate the effect of Stigmasterol on cell proliferation, results showed that Stigmasterol significantly inhibited cell viability in a time- and dose-dependent manner in SGC-7901 cells. Front Oncol. 2021 Feb 23;11:629008
OV90 cells 0, 5, 10, 20 μg/mL 48 hours Increased mitochondrial depolarization, ROS production, and calcium overload Pharmaceutics. 2020 May 28;12(6):488
ES2 cells 0, 5, 10, 20 μg/mL 48 hours Increased mitochondrial depolarization, ROS production, and calcium overload Pharmaceutics. 2020 May 28;12(6):488
Human normal colon mucosa CCD 841 CoN cells 2.5, 5, 10, 20, 40 μg/mL 48 hours To assess the effect of stigmasterol on DNA synthesis. Results showed that non-heated stigmasterol at 5 μg/mL significantly inhibited DNA synthesis, and at 40 μg/mL decreased DNA synthesis by 61%. Heated stigmasterol at 20 and 40 μg/mL reduced DNA synthesis by 31% and 39%, respectively. Sci Rep. 2023 May 1;13(1):7093
Human normal colon mucosa CCD 841 CoN cells 1.25, 2.5, 5, 10, 20, 40 μg/mL 48 hours To evaluate the cytotoxicity of stigmasterol and its esters on colon mucosa cells. Results showed that non-heated stigmasterol at 40 μg/mL reduced viable cell number by approximately 80%, while heated stigmasterol showed lower cytotoxicity at the same concentration. Sci Rep. 2023 May 1;13(1):7093
RAW 264.7 cells 0, 1, 2.5, 5, 10 µM 48 hours To evaluate the effect of STG on the viability of RAW 264.7 cells. Results showed no significant change in cytotoxicity within concentrations ranging from 0 to 10 μM, but cellular viability decreased at 20 μM. Front Pharmacol. 2024 Dec 16;15:1527494
BEAS-2B cells 10 μg/mL and 20 μg/mL 48 hours To verify the anti-inflammatory and antioxidant stress effects of stigmasterol and to reduce NK1-R expression in IL-13-induced BEAS-2B cells. Pharm Biol. 2023 Dec;61(1):449-458
RAW 264.7 cells 5, 10 µM 6-7 days To evaluate the effect of STG on osteoclast-specific gene expression. Results showed that STG significantly downregulated the expression of Acp5, NFATc1, c-Fos, and CTSK genes. Front Pharmacol. 2024 Dec 16;15:1527494
RAW 264.7 cells 0, 1, 2.5, 5, 10 µM 6-7 days To assess the effect of STG on RANKL-induced osteoclast differentiation. Results showed that STG significantly inhibited osteoclast formation in a dose-dependent manner. Front Pharmacol. 2024 Dec 16;15:1527494

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice High cholesterol diet model Oral 0.3% (w/w) 4 consecutive days Assess the effect of stigmasterol on cholesterol balance and secretion, results showed stigmasterol promoted intestinal cholesterol secretion but did not depend on LXR activation pathway. J Nutr Biochem. 2020 Feb;76:108263
C57BL/6J male mice DSS-induced colitis model Oral via diet 0.4% diet supplementation Fed for 1 week followed by 1.5% DSS in drinking water for 5 days To evaluate the protective effects of Stigmasterol against DSS-induced colitis. Results showed that Stigmasterol significantly inhibited colon shortening, reduced fecal hemoglobin content, decreased colonic inflammation score, and downregulated the expression of NF-κB, COX-2, and CSF-1. Food Funct. 2017 Nov 15;8(11):4179-4186
Mice High-fat western-style diet-induced NAFLD model Diet 0.4% in diet 17 weeks To investigate the effects of stigmasterol and β-sitosterol on high-fat western-style diet-induced NAFLD. Results showed that stigmasterol significantly ameliorated HFWD-induced fatty liver and metabolic abnormalities, including elevated levels of hepatic total lipids, triacylglycerols, cholesterol and liver histopathology. Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1274-1284
BALB/C nude mice Breast cancer stem cell transplantation model Mammary fat pad injection 10 mg/kg Once a week for 1.5 months Significantly inhibits tumor formation ability and reverses its inhibitory effect by suppressing JAK3 expression J Cancer. 2025 Feb 3;16(5):1618-1630
C57BL/6J mice OVA-induced asthma mouse model Intraperitoneal injection 100 mg/kg 7 consecutive days To evaluate the anti-inflammatory and antioxidant stress effects of stigmasterol in OVA-induced asthma mice and to verify the role of NK1-R as a potential target. Pharm Biol. 2023 Dec;61(1):449-458
Wistar rats Cerebral ischemia/reperfusion injury model Oral 20, 40, 80 mg/kg 1 week Stigmasterol alleviates cerebral ischemia/reperfusion injury by attenuating inflammation and improving antioxidant defenses in rats. Biosci Rep. 2020 Apr 30;40(4):BSR20192133
C57/BL6 male mice OVA-induced asthma mouse model Oral 5 mg/kg, 10 mg/kg, 20 mg/kg Every 2 days from day 21 to day 43 Stigmasterol alleviated OVA-induced airway inflammation, reduced the number of inflammatory cells in BALF, decreased levels of IL-1β, IL-5, IL-6, and IL-13, and inhibited the TGF-β1/Smad2 and IL-17A signaling pathways Aging (Albany NY). 2024 Apr 4;16(7):6478-6487
C57BL/6J female mice Ovariectomy (OVX) osteoporosis model Oral 5, 10 mg/kg Administered every other day for 8 weeks To evaluate the protective effect of STG against OVX-induced osteoporosis. Results showed that STG significantly reduced the number and surface area of osteoclasts and effectively prevented bone loss. Front Pharmacol. 2024 Dec 16;15:1527494
KK-Ay mice High-fat diet-induced type 2 diabetes model Oral 50 mg/kg/day, 100 mg/kg/day Once daily for 4 weeks Evaluate the hypoglycemic effect of stigmasterol in type 2 diabetic mice, results showed that stigmasterol significantly reduced fasting blood glucose levels and improved insulin resistance and oral glucose tolerance. Food Nutr Res. 2017 Aug 23;61(1):1364117
Sprague-Dawley rats Chronic constriction injury (CCI) model Oral gavage 80 mg/kg Once daily for 21 days To investigate the effect of stigmasterol on neuropathic pain in CCI rats. Results showed that stigmasterol significantly reduced thermal and cold hyperalgesia in CCI rats and decreased the levels of IL-1β, IL-6, TNF-α, CCL2, SP, and PGE2 in serum. CNS Neurosci Ther. 2024 Apr;30(4):e14657
Sprague-Dawley (SD) rats High-fat diet (HFD)-induced hyperlipidemia and hepatic steatosis model Intragastric administration Low-dose group: 100 mg/kg; High-dose group: 200 mg/kg Daily administration for 4 weeks ST treatment significantly alleviated HFD-induced hyperlipidemia and hepatic fat deposition, mainly dependent on the bile acid metabolic pathway. ST also improved intestinal barrier function and gut microbiota in HFD-fed rats, resulting in changes in bile acid metabolism. NPJ Sci Food. 2022 Aug 27;6(1):38

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00698256 Hypercholesterolemia Not Applicable Completed - Finland ... More >> University of kuopio Kuopio, Finland, 70211 Less <<
NCT02702947 BPH Phase 4 Completed - India ... More >> Department of Urology, King George's Medical University, Lucknow, UP, India Lucknow, Uttar Pradesh, India, 226003 Less <<
NCT00718796 Cardiovascular Disease Phase 3 Completed - Canada, Ontario ... More >> Canadian College of Naturopathic Medicine Toronto, Ontario, Canada, M2K 1E2 Less <<
NCT01010841 Metabolic Syndrome ... More >> Overweight Obesity Hypercholesterolemia Less << Not Applicable Completed - United States, Florida ... More >> Mark McIntosh MD Jacksonville, Florida, United States, 32209 Less <<
NCT03739242 Hypercholesterolemia Not Applicable Completed - Italy ... More >> Policlinico S.Orsola - Malpighi Medicina Interna Borghi Bologna, Italy, 40138 Less <<
NCT02221973 Primary Dyslipidemia Not Applicable Completed - China ... More >> Anzhen Hospital, Capital University of Medical Sciences Beijing, China Chao Yang 2nd Hospital Beijing, China Chui Yang Liu Hospital Beijing, China Less <<
NCT01954472 Cardiovascular Diseases ... More >> Type 2 Diabetes Hypercholesterolemia Less << Not Applicable Withdrawn(This study was combi... More >>ned with another CIHR funded study (NCT02078635). Both studies involve the same dietary portfolio and the same study population.) Less << - Canada, British Columbia ... More >> Healthy Heart Lipid Clinic, St. Paul's Hospital Vancouver, British Columbia, Canada, V6Z 1Y6 Canada, Manitoba Richardson Center for Functional Foods and Nutraceuticals and the St. Boniface Hospital Cardiovascular Center, University of Manitoba Winnipeg, Manitoba, Canada, R3T 6C5 Canada, Ontario Risk Factor Modification Centre, St. Michael's Hospital Toronto, Ontario, Canada, M5C 2T2 Canada, Quebec Institute of Nutraceuticals and Functional Foods and the Quebec Heart and Lung Institute, Laval University Quebec City, Quebec, Canada, G1V 4G2 Less <<
NCT02481466 Cardiovascular Diseases ... More >> Hypercholesterolemia Type 2 Diabetes Metabolic Syndrome Less << Not Applicable Recruiting December 2022 Canada, British Columbia ... More >> Healthy Heart Lipid Clinic, St. Paul's Hospital Recruiting Vancouver, British Columbia, Canada, V6Z 1Y6 Principal Investigator: Jiri Frohlich, MD          Canada, Manitoba Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba Not yet recruiting Winnipeg, Manitoba, Canada, R3T 6C5 Contact: Peter Jones, PhD          Principal Investigator: Peter Jones, PhD          Canada, Ontario Risk Factor Modification Centre, St. Michael's Hospital Recruiting Toronto, Ontario, Canada, M5C 2T2 Contact: David J Jenkins, MD PhD    416-867-7475    David.jenkins@utoronto.ca    Contact: Dorothea A Faulkner, PhD    416-360-4000 ext 48175    FaulknerD@smh.ca    Principal Investigator: David J Jenkins, MD PhD          Sub-Investigator: Cyril Kendall, PhD          Sub-Investigator: Robert Josse, MD          Sub-Investigator: Lawrence Leiter, MD          Sub-Investigator: John Sievenpiper, MD PhD          Sub-Investigator: Anish Kirpalani, MD          Canada, Quebec Institute of Nutraceuticals and Functional Foods, Laval University Recruiting Quebec City, Quebec, Canada, G1V 4G2 Contact: Benoit Lamarche, PhD          Principal Investigator: Benoit Lamarche, PhD Less <<
NCT00345722 Hyperlipidemia ... More >> Cardiovascular Diseases Hypercholesterolemia Less << Phase 2 Completed - Canada, Ontario ... More >> Clinical Nutrition & Risk Factor Modification Centre, St. Michael's Hospital Health Centre Toronto, Ontario, Canada, M5C 2T2 Less <<
NCT03681392 Prostatism Er... More >>ectile Dysfunction Less << Not Applicable Not yet recruiting March 2020 -
NCT01031485 Stage 1 Hypertension Phase 3 Completed - Finland ... More >> Valio Ltd Helsinki, Uusimaa, Finland, 00370 Less <<
NCT03728244 Graft Pain Gi... More >>ngival Recession Less << Phase 1 Phase 2 Not yet recruiting August 2020 -
NCT00249938 Hyperlipidemia ... More >> Dyslipidemia Less << Phase 4 Completed - United States, Colorado ... More >> University of Colorado at Denver and Health Sciences Center Denver, Colorado, United States, 80262 Less <<
NCT03534414 - Active, not recruiting October 1, 2018 Canada, Ontario ... More >> The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Micheal's Hospital Toronto, Ontario, Canada, M5C 2T2 Less <<
NCT01584206 Sitosterolemia Not Applicable Unknown December 2016 Canada, Manitoba ... More >> Richardson Centre for Functional Foods and Nutraceuticals Winnipeg, Manitoba, Canada, R3T 2N2 Less <<
NCT00438425 Hyperlipidemia ... More >> Cardiovascular Disease Less << Not Applicable Completed - Canada, British Columbia ... More >> Healthy Heart Program, St. Paul's Hospital Vancouver, British Columbia, Canada, V6Z 1Y6 Canada, Manitoba Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba Winnipeg, Manitoba, Canada, R3T 6C5 Canada, Ontario Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 St. Michael's Hospital Toronto, Ontario, Canada, M5C 2T2 Canada, Quebec Institute on Nutraceuticals and Functional Foods and the Lipid Research Center, Laval University Hospital Research Center Quebec City, Quebec, Canada, G1V 4G2 Less <<
NCT00793364 Hypercholesterolemia Phase 4 Completed - Greece ... More >> Aristotelian University, Hippocration Hospital Thessaloniki, Greece, 55132 Less <<
NCT01948648 Sitosterolemia Not Applicable Recruiting December 31, 2019 Canada, Manitoba ... More >> Richardson Center for Functional Foods and Nutraceuticals Recruiting Winnipeg, Manitoba, Canada Contact: Semone B Myrie, PhD    204-272-1555    myrie@cc.umanitoba.ca    Contact: Peter J Jones, PhD    204-474-8883    Peter.Jones@umanitoba.ca    Sub-Investigator: Semone B Myrie, PhD          Principal Investigator: Peter J Jones, PhD          Sub-Investigator: David Mymim, PhD          Sub-Investigator: Taback Shayne, PHD Less <<
NCT01084226 Hypercholesterol Phase 2 Completed - Finland ... More >> Folkhälsan Research Center Helsinki, Finland, 00290 Less <<
NCT02078635 Cardiovascular Diseases ... More >> Hypercholesterolemia Diabetes Metabolic Syndrome Obesity Less << Not Applicable Withdrawn(Study was amalgamate... More >>d with another study to include exercise as another intervention.) Less << - Canada, British Columbia ... More >> Healthy Heart Lipid Clinic, St. Paul's Hospital Vancouver, British Columbia, Canada, V6Z 1Y6 Canada, Manitoba Richardson Center for Functional Foods and Nutraceuticals and the St. Boniface Hospital Cardiovascular Center, University of Manitoba Winnipeg, Manitoba, Canada, R3T 6C5 Canada, Ontario Risk Factor Modification Centre, St. Michael's Hospital Toronto, Ontario, Canada, M5C 2T2 Canada, Quebec Institute of Nutraceuticals and Functional Foods and the Quebec Heart and Lung Institute, Laval University Quebec City, Quebec, Canada, G1V 4G2 Less <<
NCT01629238 - Completed - France ... More >> BKL Consultant Boulogne-Billancourt, France, 92100 Less <<
NCT00924391 Coronary Heart Disease Phase 2 Completed - Canada, Manitoba ... More >> Richardson Centre for Functional Foods and Nutraceuticals Winnipeg, Manitoba, Canada, R3T 2N2 Less <<
NCT00923403 Hypercholesterolemia Phase 1 Phase 2 Completed - Canada, Manitoba ... More >> Richardson Centre for Functional Foods and Nutraceuticals Winnipeg, Manitoba, Canada, R3T 6C5 Less <<
NCT00438893 Hyperlipidemia ... More >> Cardiovascular Diseases Hypercholesterolemia Less << Not Applicable Completed - Canada, Ontario ... More >> Clinical Nutrition & Risk Factor Modification Centre, St. Michael's Hospital Health Centre Toronto, Ontario, Canada, M5C 2T2 Less <<
NCT00846937 Ileostoma Not Applicable Completed - Finland ... More >> University of Helsinki, Department of Medicine Helsinki, Finland, 00029 Less <<
NCT00940849 Gastric Emptying Not Applicable Completed - Netherlands ... More >> Maastricht University Medical Center Maastricht, Limburg, Netherlands, 6200 Less <<
NCT00802516 Hypercholesterolemia Not Applicable Completed - Netherlands ... More >> Maastricht University Maastricht, Netherlands, 6229ER Less <<
NCT03469518 Hypercholesterolemia ... More >> Osteoporosis Postmenopausal Disorder Less << Not Applicable Active, not recruiting December 2018 -
NCT03065491 Hypercholesterolemia Not Applicable Completed - Italy ... More >> S. Orsola-Malpighi University Hospital Bologna, BO, Italy, 40138 Less <<
NCT00441857 Hypercholesterolemia Phase 4 Completed - Finland ... More >> Oy Foodfiles Ltd Kuopio, Finland, 70210 Less <<
NCT01521169 Normal and Mild Hypercholester... More >>olemic Subjects Less << Not Applicable Completed - Japan ... More >> Senrichuo Ekimae Clinic - Senri Life Science Center 13F Osaka, Japan, 560-0082 Less <<
NCT03312816 Healthy Not Applicable Completed - Germany ... More >> Charité Research Organisation GmbH Berlin, Germany, 10117 Less <<
NCT02732223 Cardiovascular Diseases Not Applicable Completed - -
NCT01932840 - Completed - Canada, Ontario ... More >> University of Guelph Guelph, Ontario, Canada Less <<
NCT01600820 Hypercholesterolemia Not Applicable Completed - Spain ... More >> Hospital de Sant Joan Reus, Spain, 43201 Less <<
NCT00422266 Dyslipidemia Phase 3 Completed - India ... More >> National Thermal Power Corporation Delhi, Badarpur, India Less <<
NCT00485095 High Blood Cholesterol Level Phase 4 Completed - Norway ... More >> Lipidklinikken, Rikshospitalet Radiumhospitalet HF Oslo, Norway Rikshospitalet Radiumhospitalet HF, Oslo, Norway Oslo, Norway Less <<
NCT01882517 Hypercholesterolemia ... More >> Hyperlipidemias Dyslipidemias Less << Not Applicable Completed - Turkey ... More >> Hacettepe University Ankara, Turkey Less <<
NCT01716390 Hypercholesterolemia Not Applicable Completed - Sweden ... More >> Good Food Practice Uppsala, Sweden Less <<
NCT00222950 - Unknown - Germany ... More >> University of the Saarland Recruiting Homburg, Saarland, Germany, 66421 Contact: Oliver Weingartner, M.D.    0049-(0)68411623372    oweingartner@aol.com    Contact: Ulrich Laufs, M.D.    0049-(0)68411623372    ulrich@laufs.com    Sub-Investigator: Oliver Weingartner, M.D. Less <<
NCT01825668 Hypercholesterolemia ... More >> CVD Less << Not Applicable Unknown June 2016 Canada, Manitoba ... More >> Richardson Centre for Functional Foods and Nutraceuticals Winnipeg, Manitoba, Canada, R3T 2N2 Less <<
NCT01340287 Hypercholesterolemia Not Applicable Completed - United States, Florida ... More >> Renstar Medical Research Ocala, Florida, United States Less <<
NCT01478789 Hypercholesterolemia Not Applicable Completed - Canada, Manitoba ... More >> Richarson Centre for Funtional Foods and Nutraceuticals Winnipeg, Manitoba, Canada, R3T 2N2 Less <<
NCT01461798 Risk Reduction Behavior Not Applicable Unknown March 2012 -
NCT00897975 Hyperlipidemia Phase 2 Phase 3 Completed - United States, Pennsylvania ... More >> Abington Memorial Hospital Abington, Pennsylvania, United States Chestnut Hill Hospital Philadelphia, Pennsylvania, United States, 19118 Less <<
NCT02628990 Hypercholesterolemia ... More >> Hyperlipidemias Dyslipidemias Less << Not Applicable Completed - -
NCT01629888 Healthy Mild ... More >>Hypercholesterolemia Less << Not Applicable Completed - Japan ... More >> Senri Chuo Ekimae Clinic Osaka, Japan, 560-0082 Less <<
NCT00145717 Hypercholesterolemia ... More >> Cardiovascular Diseases Less << Phase 3 Completed - China ... More >> Peking University Health Science Centre Beijing, China, 100083 Less <<
NCT02947594 - Completed - -
NCT01574469 Mildly Hypercholesterolemic Su... More >>bjects Less << Not Applicable Completed - France ... More >> Hôpital Pitié-Salpêtrière Paris, France, 75013 Less <<
NCT02475018 Hypercholesterolemia Not Applicable Completed - China, Beijing ... More >> BaiZhiFang Community Health Service Centre Beijing, Beijing, China, 100053 Less <<
NCT01313988 Healthy Mildl... More >>y Elevated Cholesterol Levels Less << Not Applicable Completed - Sweden ... More >> KPL Good Food Practice AB Uppsala, Sweden, S-751 83 Less <<
NCT00863265 Hypercholesterolemia ... More >> Coronary Heart Disease Less << Early Phase 1 Completed - United States, Utah ... More >> Center for Advance Nutrition at Utah State University Logan, Utah, United States, 84322-4715 Less <<
NCT02779673 LDL-cholesterol Level 130-159m... More >>g/dL Less << Not Applicable Completed - -
NCT02221297 Hypercholesterolemia ... More >> Hyperlipidemias Dyslipidemias Less << Not Applicable Completed - -
NCT01574482 Mildly Hypercholesterolemic Su... More >>bjects Less << Not Applicable Completed - Italy ... More >> Ospedale Silvestrini Perugia, Italy, 06129 Less <<
NCT00863265 - Completed - -
NCT01571869 Mildly Hypercholesterolemic Su... More >>bjects Less << Not Applicable Completed - Canada, Quebec ... More >> McGill University Ste-anne-de-bellevue, Quebec, Canada, H9X 3V9 Less <<
NCT02316808 Dyslipidemias ... More >> Hypercholesterolemia Hyperlipidemias Less << Not Applicable Completed - -
NCT00153738 Hypercholesteremia Not Applicable Completed - United States, Texas ... More >> The Cooper Institute Dallas, Texas, United States, 75230 Less <<
NCT01521156 Mild Hypercholesterolemic Subj... More >>ects Less << Not Applicable Completed - Germany ... More >> Harrison Clinical Research Clinical Unit Munich, Germany, 80636 Less <<
NCT03705767 - Completed - -
NCT01571882 Mildly Hypercholesterolemic Su... More >>bjects Less << Not Applicable Completed - United Kingdom ... More >> Guildford Clinical Pharmacology Unit Ltd. (Gcpl) Guildford, Surrey, United Kingdom, GU2 7YG Less <<
NCT02459314 Hypercholesterolemia Not Applicable Completed - Thailand ... More >> Clinical trial Unit, Faculty of Medicine, Chiang Mai University Muang, ChiangMai, Thailand, 50200 Less <<
NCT02644109 Dyslipidemias ... More >> Hypercholesterolemia Less << Phase 4 Completed - Chile ... More >> Instituto de Nutricion y Tecnologia de los Alimentos, Universidad de Chile Santiago, Región Metropolitana de Santiago, Chile Department of Nutrition, Diabetes and Metabolism. Pontificia Universidad Catolica de Chile Santiago, Chile Less <<
NCT01205308 Type 1 Diabetes Not Applicable Completed - Finland ... More >> University of Eastern Finland Kuopio, Finland, FIN-70211 Less <<
NCT02765516 Hypercholesterolemia ... More >> Cardiovascular Disease Less << Not Applicable Recruiting December 2019 Canada, Manitoba ... More >> Department of Human Nutritional sciences, University of Manitoba Recruiting Winnipeg, Manitoba, Canada, R3T2N2 Contact: James House, PhD    204-474-6837    james.house@umanitoba.ca    Principal Investigator: James House, PhD Less <<
NCT03284918 Hypercholesterolemia ... More >> Hyperlipidemias Dyslipidemias Less << Not Applicable Completed - -
NCT00738933 Hypercholesterolemia ... More >> Atherosclerosis Less << Not Applicable Unknown December 2011 Finland ... More >> Department of Medicine, Div. of Internal Medicine, Helsinki Univ. Central Hospital (HUCH) Recruiting Helsinki, Finland, 00029HUS Contact: Markku Nissinen, MD, PhD    +358 9 4711    markku.nissinen@hus.fi    Principal Investigator: Tatu A Miettinen, Professor          Sub-Investigator: Markku J Nissinen, MD, PhD Less <<
NCT02644109 - Completed - -
NCT01715675 Asthma Allerg... More >>y Less << Not Applicable Completed - Netherlands ... More >> Maastricht University Medical Centre Maastricht, Limburg, Netherlands, 6229ER Less <<
NCT00720720 Hypercholesterolemia Not Applicable Terminated(Recruitment and org... More >>anizational difficulties) Less << - France ... More >> Hôpital cardio-vasculaire et pneumologique Louis Pradel Bron, France, 69677 Clinique d'Endocrinologie, Maladies Métaboliques et Nutrition Nantes, France, 44093 Groupe Hospitalier Pitié-Salpêtrière, Endocrinology and Metabolism Department Paris, France, 75013 Less <<
NCT00920894 Elevated Blood Lipids Not Applicable Completed - Finland ... More >> Clinical Life Sciences Ltd Vuokatti, Finland, 88610 Less <<
NCT00441480 - Completed - -
NCT03723330 Cardiovascular Diseases ... More >> Endothelial Dysfunction Metabolic Syndrome Diet Modification Less << Not Applicable Not yet recruiting May 2020 -
NCT00441480 Dyslipidemia Phase 4 Completed - Israel ... More >> Sheba medical center Tel-HaShomer, Israel, 52621 Less <<
NCT02603276 Hypercholesterolemia Not Applicable Completed - Italy ... More >> S. Orsola-Malpighi University Hospital Bologna, Italy, 40038 Less <<
NCT00737919 Atherosclerosis Not Applicable Completed - Finland ... More >> Department of Surgery, Div. of Vascular Surgery, Helsinki University Central Hospital Helsinki, Finland, 00029 Less <<
NCT02969720 Metabolic Syndrome x Phase 3 Unknown December 2017 -
NCT00860054 Hypercholesterolemia ... More >> Coronary Heart Disease Less << Not Applicable Completed - United States, Louisiana ... More >> Pennington Biomedical Research Center Baton Rouge, Louisiana, United States, 70808 Less <<
NCT02728583 Vascular Diseases ... More >> Hypercholesterolemia Less << Not Applicable Completed - Germany ... More >> Charite Research Organisation Berlin, Germany Less <<
NCT02278393 Healthy Volunteers Not Applicable Completed - Japan ... More >> Yaesu Sakura-dori Clinic Tokyo, Japan, 103-0028 Less <<
NCT01712867 Patients With Hypertriglycerid... More >>emia Less << Not Applicable Completed - Israel ... More >> Maccabi Healthcare Services Tel-Aviv, Israel Less <<
NCT01803178 Vascular Diseases ... More >> Hypercholesterolemia Less << Not Applicable Completed - Germany ... More >> Charité Research Organisation Berlin, Germany Less <<
NCT00860509 Hypercholesterolemia ... More >> Coronary Heart Disease Less << Not Applicable Completed - United States, Louisiana ... More >> Pennington Biomedical Research Center-Louisana State University System Baton Rouge, Louisiana, United States, 70808 Less <<
NCT02065024 Hypercholesterolemia ... More >> Osteoporosis Less << Phase 1 Completed - Spain ... More >> Hospital Universitario Puerta de Hierro-Majadahonda Majadahonda (Madrid), Madrid, Spain, 28222 Less <<
NCT02268318 Subjects With High LDL-Cholest... More >>erol Less << Not Applicable Completed - Japan ... More >> Yaesu Sakura-dori Clinic Tokyo, Japan, 103-0028 Less <<
NCT02758834 - Completed - -
NCT02881658 Dyslipidemia Not Applicable Completed - Hong Kong ... More >> Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam Hong Kong, Hong Kong Less <<
NCT02881658 - Completed - -
NCT01574417 Hypercholesterolemia Not Applicable Completed - Netherlands ... More >> Maastricht University Medical Centre Maastricht, Limburg, Netherlands Less <<
NCT01559428 Normocholesterolemic Not Applicable Completed - Netherlands ... More >> Maastricht University Medical Centre Maastricht, Limburg, Netherlands, 6229 ER Less <<
NCT01406106 Hypercholesterolemia Not Applicable Unknown December 2012 -
NCT01315964 Atherosclerosis Not Applicable Completed - Finland ... More >> Biomedicum Helsinki Helsinki, Finland, 00029 Less <<
NCT01102647 Cardiovascular Disease Phase 1 Completed - Canada, Manitoba ... More >> University of Manitoba Winnipeg, Manitoba, Canada, R3T 2N2 Less <<
NCT02288585 Vascular Diseases ... More >> Hypercholesterolemia Diabetes Mellitus Less << Not Applicable Completed - Australia ... More >> CSIRO Adelaide, Australia CSIRO, North Ryde Sydney, Australia Less <<
NCT01074723 Postmenopausal Disorder Phase 1 Completed - Spain ... More >> Puerta de Hierro University Hospital Madrid, Spain, 28222 Less <<
NCT03627819 Non-Alcoholic Fatty Liver Dise... More >>ase Less << Not Applicable Recruiting December 2019 Netherlands ... More >> Maastricht University Medical Centre Recruiting Maastricht, Limburg, Netherlands, 6229 ER Contact: Sabine Baumgartner, Dr.    +31 (0)43 3881305    sabine.baumgartner@maastrichtuniversity.nl Less <<
NCT02089867 Coronary Artery Disease Phase 2 Phase 3 Completed - Brazil ... More >> Jose Rocha Faria Neto Curitiba, Paraná, Brazil, 80215-901 Less <<
NCT02331043 Dyslipidemias ... More >> Hypercholesterolemia Hyperlipidemias Less << Not Applicable Completed - Thailand ... More >> Mahidon University, Nutrition Institute, Center of Innovation and Reference on Food for Nutrition (CIRFON) Phutthamonthon, Nakhon Pathom, Thailand, 73170 Less <<
NCT01131832 Hyperlipidemia Phase 4 Completed - United States, Maryland ... More >> USDA-ARS, Beltsville Human Nutrition Research Center Beltsville, Maryland, United States, 20705 Canada, Manitoba Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba Winnipeg, Manitoba, Canada, R3T 6C5 Less <<
NCT01875978 Non-alcoholic Fatty Liver Dise... More >>ase Less << Not Applicable Completed - Taiwan ... More >> China Medical University Hospital Taichung, Taiwan Less <<
NCT01875978 - Completed - -
NCT02541201 Dyslipidemia Phase 2 Completed - -
NCT00928616 Hyperlipidemia Not Applicable Unknown June 2009 Germany ... More >> Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III Homburg, Saarland, Germany, 66421 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.42mL

0.48mL

0.24mL

12.12mL

2.42mL

1.21mL

24.23mL

4.85mL

2.42mL

References

 

Historical Records

Categories